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Abstract
While ﬁbroblast growth factor receptor 3 (FGFR3) is frequently mutated or
overexpressed in nonmuscle-invasive urothelial carcinoma (UC), the prevalence
of FGFR3 protein expression and mutation remains unknown in muscle-inva-
sive disease. FGFR3 protein and mRNA expression, mutational status, and copy
number variation were retrospectively analyzed in 231 patients with formalin-
ﬁxed parafﬁn-embedded primary UCs, 33 metastases, and 14 paired primary
and metastatic tumors using the following methods: immunohistochemistry,
NanoString nCounterTM, OncoMap or Affymetrix OncoScanTM array, and
Gain and Loss of Analysis of DNA and Genomic Identiﬁcation of Signiﬁcant
Targets in Cancer software. FGFR3 immunohistochemistry staining was present
in 29% of primary UCs and 49% of metastases and did not impact overall sur-
vival (P = 0.89, primary tumors; P = 0.78, metastases). FGFR3 mutations were
observed in 2% of primary tumors and 9% of metastases. Mutant tumors
expressed higher levels of FGFR3 mRNA than wild-type tumors (P < 0.001).
FGFR3 copy number gain and loss were rare events in primary and metastatic
tumors (0.8% each; 3.0% and 12.3%, respectively). FGFR3 immunohistochem-
istry staining is present in one third of primary muscle-invasive UCs and half
of metastases, while FGFR3 mutations and copy number changes are relatively
uncommon.
Introduction
The treatment of metastatic urothelial carcinoma (UC) of
the bladder has not advanced signiﬁcantly in over
20 years. Platinum-based combination chemotherapy
remains the standard treatment for this disease, and no
effective salvage therapies are FDA-approved in the United
States. Understanding the biology of UC to identify new
druggable targets is required to improve clinical outcomes.
The ﬁbroblast growth factor (FGF) family of trans-
membrane tyrosine kinase receptors mediates prolifera-
tion in response to FGF stimulation and has been
implicated in the pathogenesis of UC. Fibroblast growth
factor receptor 1 (FGFR1) is overexpressed in a subset of
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Open AccessUC specimens, and some invasive UC cells lines are
dependent on FGFR1 protein for proliferation [1].
Materials and Methods
Patients
Primary UC formalin-ﬁxed parafﬁn-embedded (FFPE)
bladder specimens from either transurethral resections or
cystectomies were provided by the Hospital del Mar, Bar-
celona, Spain (N = 107) and the Hellenic Cooperative
Oncology Group (HCOG), Athens, Greece (N = 110)
under Institutional Review Board (IRB) approved proto-
cols. Primary (N = 14) UC FFPE specimens from radical
cystectomies and metastatic (N = 33) UC FFPE specimens
from metastectomies were identiﬁed from the Brigham
and Women’s Hospital (BWH) Pathology Department,
Boston, under IRB-approved protocols. All patients with
primary UC tumors had muscle-invasive tumors and
went on to develop metastatic UC. Paired primary and
metastatic tumors were available for 14 patients who
overlapped between the primary tumor and metastases
cohorts. Normal bladder tissue (from cystectomies for
nonmalignant indications) was obtained from the BWH
with IRB approval. Two genitourinary pathologists
reviewed the slides and identiﬁed tumor and normal tis-
sue; D. B. reviewed tissue from the BWH and Spanish
cohorts and J. B. reviewed tissue from the Greek cohort.
Tissue cores of 0.6 mm were taken from each specimen
for DNA and total RNA extraction and tissue microarrays
(TMA) construction. Three cores of each case were embed-
ded in the tissue microarray, and normal urothelium cores
from normal bladder tissue from non-cancer patients were
included as controls. Genomic DNA was extracted from
tumors with the QiaAmp DNA FFPE Tissue Kit (Quiagen,
Valencia, CA) on the Quiagen Robot according to the
manufacturers’ instructions. Total RNA was extracted
from tumors with the FFPE kit on the Beckman Coulter
Biomek platform (Beckman Coulter, Beverly MA) accord-
ing to the manufacturers’ instructions.
Immunohistochemistry
Tissue microarrays with primary and metastatic tumors
and normal bladder controls were stained with a com-
mercially available anti-FGFR3 antibody (Santa Cruz,
Dallas, TX, clone B-9, SC-13121). Antigen retrieval was
performed in ethylene-diamine-tetra-acetic acid buffer
using a microwave set on high for 5 min, repeated three
times. Following antigen retrieval, slides were transferred
to a BioGenex i6000 (Fremont, CA) automated staining
deck. Slides were rinsed in a phosphate-buffered
saline tween wash for 15 min, incubated in a commercial
peroxidase blocking solution (Dako, Carpinteria, CA) for
30 min, and then incubated with commercial protein
block (Dako) for 20 min. The slides were then incubated
with the primary antisera to FGFR3 at a dilution of 1:50
for 1 h. The primary antisera was visualized using a per-
oxidase-based detection kit (Dako Envision), following
the manufacturers’ instructions. The slides were counter-
stained with hematoxylin (BioGenex) and coverslipped.
Tissue microarrays cores for the four TMA’s were evalu-
ated by a single pathologist (R. L.). Stain in the tumor cells
was designated as nuclear, cytoplasmic, and/or membra-
nous. Intensity of the stain was scored as absent (negative),
weak, weak–moderate, moderate, or strong based on previ-
ously reported scoring systems [2, 3]. The presence of any
staining was considered positive. Immunohistochemistry
staining was repeated when necessary to demonstrate what
was judged to be uniform staining of the slide. Any uneven
individual core staining or edge effect, and any cores exhib-
iting extreme electrocautery changes or insufﬁcient tumor
present were excluded from the scoring analysis. Any back-
ground stain in the stroma was used as baseline in deter-
mining the epithelial score. Of the three cores represented
for each patient case in the TMA, actual cases had either 0,
1, 2, or 3 cores available for scoring (due to exclusionary
issues stated above), and this is reﬂected in the raw data.
mRNA analysis
Total RNA was extracted from tumor specimens following
manufacturer protocols (Ambion RecoverAll, Life Tech-
nologies, Grand Island, NY). mRNA transcript expression
of FGFR3 was quantiﬁed using color-coded oligonucleo-
tides synthesized by NanoString nCounterTM gene expres-
sion system and hybridized to these transcripts, as has
been previously described for FFPE archival samples [4].
Transcripts were counted using the automated NanoString
nCounter
  system (NanoString Technologies, Seattle,
WA). Counts were normalized with the nSolver Analysis
Software (version 1.0) in which mRNA expression was
compared to internal NanoString controls, several house-
keeping genes (ACTB, GAPDH, HPRT1, LDHA, PFKP,
PGAM1, STAT1, TUBA4A, VIM), and UC-invariant genes
(ANGEL1, DDX19A, NAGA, RPS10, RPS16, RPS24,
RPS29), which were identiﬁed by analyzing gene expres-
sion variances in several published datasets [5, 6]. Differ-
ential expression of FGFR3 mutants versus wild-type (WT)
tumors was calculated with the edgeR package [7].
FGFR3 mutation analysis
Two technologies were used to test specimens for FGFR3
mutations: OncoMap mass spectrometric genotyping
based on the Sequenom MassARRAY
  technology
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OncoScan FFE Express molecular inversion probe (MIP)
arrays [10] (Table 1). The OncoMap platform consists of
two assays, iPLEX genotyping and multibase homogenous
Mass-Extend (hME) extension chemistry; only mutations
detected by both methods were considered “validated
mutations” in OncoMap. For both OncoMap and MIP
arrays, genomic DNA was quantiﬁed using Quant-iT
PicoGreen dsDNA Assay Kit (Invitrogen, Grand Island,
NY) per manufacturer’s protocol.
OncoMap mass spectrometric genotyping based on the
Sequenom MassARRAY
  technology (Sequenom Inc.)
was performed as previously described with some modiﬁ-
cations [11]. A total of 250 ng of DNA was used for
mutation analysis. Probes were designed that enabled
mutation detection. Hundred nanograms of tumor-
derived genomic DNA was subjected to whole genome
ampliﬁcation (WGA). Next, up to 18-multiplexed PCR
was performed on tumor genomic DNA to amplify
regions harboring loci of interest. After denaturation,
PCR products were incubated with the probes that anneal
immediately adjacent to the query nucleotide. Mass
spectrometric genotyping using iPLEX chemistries was
performed (Sequenom Inc.) extending the probes with
one base in the presence of chain-terminating di-deoxy-
nucleotides that generate allele-speciﬁc DNA products.
The extension products were spotted onto a specially
designed chip and analyzed by matrix-assisted laser
desorption/ionization time-of-ﬂight (MALDI-TOF) mass
spectrometry to determine the mutation status based on
the difference in mass of the mutant and WT base.
Next, an automated mutation-calling algorithm was
performed to identify candidate mutations. Putative
mutations were further ﬁltered by a manual review and
selected for validation using multibase hME chemistry
with a maximum pooling of six assays on the remaining
150 ng DNA of each sample. Primers and probes used for
hME validation were designed using the Sequenom Mass-
ARRAY Assay Design 3.0 (Farmingdale, NY) software,
applying default multibase extension parameters. OncoM-
ap “validated mutations” were identiﬁed by both iPLEX
and hME.
Affymetrix OncoScanTM FFPE Express MIP arrays
were performed as previously reported [10]. DNA from
primary and metastatic tumors was hybridized to Affyme-
trix OncoScanTM FFPE Express 2.0 SNP MIP arrays.
Median probe spacing was 9 kb. NEXUS software
(Concord, OH) was used to estimate copy numbers.
FGFR3 pathway copy number analysis
Normalized copy number data were segmented using
Gain and Loss Analysis of DNA (GLAD) with default
parameters available in GenePattern (version 3.3.3; Cam-
bridge, MA) [12].
The Genomic Identiﬁcation of Signiﬁcant Targets in
Cancer (GISTIC) (version 2.0.12; Cambridge, MA) soft-
ware was used with a conﬁdence level of 0.95 and other-
wise default parameters to identify regions of the genome
that were signiﬁcantly ampliﬁed or deleted across a set of
samples [13]. High-level ampliﬁcations and deletions were
identiﬁed using log base 2 ratio thresholds of 0.9 and
<0.3, respectively.
Biostatistics
Patient and clinical characteristics were summarized as
numbers and percentages. FGFR3 staining intensity was
tabulated by category and summarized as numbers and
percentages with 95% conﬁdence intervals (CI). Exact
binominal test was used to calculate 95% CI. Fisher’s
exact test was used to assess the associations of FGFR3
mutation and types of tumor. The median overall survival
(OS) for the primary cohort was measured from the start
of chemotherapy for metastatic disease. The median OS
for the metastatic cohort was measured from the time of
diagnosis of metastatic disease rather than initiation of
chemotherapy because this clinical information was not
available for all patients. However, when these data were
available, the median time from diagnosis of metastases
to the start of chemotherapy was 1.2 months, which sug-
gested that the difference in OS as measured by these two
deﬁnitions was not clinically signiﬁcant. Kaplan–Meier
estimate was used to summarize median OS. Cox regres-
sion model was used to assess the association of FGFR3
staining and OS and hazard ratio with 95% CI was
Table 1. FGFR3 mutations included in assays.
FGFR3
mutations
ONCOMAP
(versions
1 and 3) MIP
Y241C ●
R248C ●●
S249C ●●
H284fs*10 ●
E322K ●
G370C ●●
S371C ●
Y373C ●●
F384L ●
A391E ●●
K650E ●
K650Q ●●
K650M ●●
K650T ●
Filled circles indicate in which of the assays (or both) the listed muta-
tions are included.
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parameters, such as FGFR3 mutation or copy number
variation (CNV), was not performed because of limited
sample sizes with the presence of these alterations.
Results
Patients and tumors
A total of 231 patients with primary tumor samples avail-
able were included in the primary cohort; 206 patients in
this cohort had documentation of the development of
metastatic disease (Table 2). The metastasis cohort
included 33 patients with metastatic tumor samples, for
which clinical data were available for 31 patients.
FGFR3 immunohistochemistry
Immunohistochemical staining data were evaluable from
231 primary tumors and 31 metastases (Fig. 1). Positive
staining for FGFR3 was detected in 29% (95% CI = [23–
35%]) of primary tumors and 49% (95% CI = [30–67])
of metastatic tumors (Fig. 2). Less than 1% of primary
tumors and 3% of metastases had strong staining. There
is no statistically signiﬁcant difference in the percentage
staining between primary tumors and metastases (41% vs.
49%, respectively). Of 14 paired primary and metastatic
tumors, three pairs were positive for FGFR3 staining,
whereas seven pairs were negative for FGFR3 staining.
Among primary tumors with positive staining, 60% of
paired metastases were also positive.
FGFR3 staining in the primary tumor was not associ-
ated with OS (HR = 1.03, 95% CI [0.7–1.50], P = 0.89)
in patients who developed metastatic disease (N = 206)
(Fig. 3A). In metastatic tumor specimens (N = 31),
FGFR3 staining did not correlate with OS (HR = 1.12,
95% CI [0.49–2.58], P = 0.78) (Fig. 3B). Due to limited
sample size, we were unable to determine whether speciﬁc
subcellular locations of FGFR3 immunostaining were
associated with FGFR3 expression in metastases or with
OS.
FGFR3 mRNA analysis
Tumors with FGFR3 mutations had a statistically signiﬁ-
cant increase in FGFR3 mRNA expression compared with
WT tumors (P < 0.001) (Fig. 4). One of two FGFR3-
mutant tumors for which both mRNA and IHC data were
available had weak FGFR3 protein expression by IHC; the
other tumor had negative FGFR3 expression.
FGFR3 mutation
Primary UC specimens (N = 131) were tested for FGFR3
mutations with either OncoMap- (version 1 and version
3) targeted hotspot sequencing or Affymetrix Onco-
ScanTM FFPE Express MIP arrays (N = 30). A subset of
eight primary tumors underwent mutation testing with
both platforms. Metastatic UC specimens from Dana-Far-
ber Cancer Institute (N = 33) were tested for FGFR3
mutations using Affymetrix MIP arrays.
There was no signiﬁcant difference in the frequency of
FGFR3 mutations between primary tumors (2%) and
metastatic tumors (9%) (Table 3) (P = 0.1). One primary
tumor tested with both OncoMap and OncoScan demon-
strated evidence of Y373C mutation using OncoMap, but
the overall mutation frequency did not meet the threshold
in OncoScan for a positive mutation. The remaining
seven samples tested using both OncoMap and OncoScan
were negative for mutations in each platform. None of
the three metastases with Y373C mutations had paired
primaries, although one had a paired normal bladder
specimen that did not demonstrate evidence of Y373C
Table 2. Patient clinical characteristics.
N (%)
Primary tumor cohort (N = 231)
Median OS
1 (16 months)
ECOG PS
0 90 (39)
1 + 2 102 (78)
Missing 39 (17)
Visceral disease
3
No 113 (49)
Yes 87 (38)
Missing 31 (13)
ECOG PS >0 and presence of visceral disease 40 (17)
Survival
Alive 77 (33)
Dead 136 (59)
Missing 18 (8)
Metastatic cohort (N = 31)
Median OS
2 (11 months)
Metastatic site
Visceral 16 (52)
Local 7 (23)
Lung 13 (42)
Lymph node 12 (39)
Liver 8 (26)
Bone 4 (13)
Other 9 (29)
1Median OS measured from time of initiation of chemotherapy for
metastatic disease to death.
2Median OS measured from time of diagnosis of metastatic disease to
death.
3Visceral disease is deﬁned as metastases to internal organs such as
lung or liver but not lymph nodes.
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FGFR3 in Bladder UC E. A. Guancial et al.Figure 1. FGFR3 immunostaining in muscle-invasive UC of the bladder with metastatic phenotype. (A and E) Low- and high-power (209 and
409) FGFR3 expression in invasive urothelial carcinoma, graded as moderate with both cytoplasmic and membranous staining. (B and F) Low- and
high-power (209 and 409) FGFR3 expression in metastatic urothelial carcinoma, graded as weak with cytoplasmic staining evident. (C and G)
Low- and high-power (209 and 409) FGFR3 expression in metastatic urothelial carcinoma, graded as strong, with prominent cytoplasmic and
membranous staining. (D and H) Low- and high-power (209 and 409) FGFR3 expression in metastatic urothelial carcinoma, graded as moderate,
with prominent cytoplasmic staining.
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paired primary and metastatic specimens. Two of three
metastases with FGFR3 mutations demonstrated positive
FGFR3 expression by IHC: one had moderate staining
and the second had strong staining.
FGFR3 copy number analysis
Normal bladder specimens demonstrated no CNVs in
FGFR3 (Table 4). FGFR3 copy number gain and loss were
rare events in primary tumors (0.8% each). Copy number
gain and loss was observed in 3.0% and 12.1% of metasta-
ses, respectively. Co-occurrence of mutation and copy
number gain of FGFR3 was observed in one specimen.
Copy number gains or losses detected among metastatic
samples were not seen in the primary tumor when available.
Discussion
Our results demonstrate that some FGFR3 IHC staining
is present in nearly one third of primary muscle-invasive
UC tumors and half of metastases. While the sample size
was relatively small, over half of metastases from paired
primary tumors with FGFR3 expression retain FGFR3
protein expression, albeit at low levels in most specimens.
Tissue cores were obtained from pathologist-reviewed
H&E tumor specimens and incorporated into a TMA.
Since the whole tissue section was not available to be
stained for FGFR3, we do not know if FGFR3 expression
is homogenous throughout the tumor. The presence or
absence of FGFR3 IHC staining does not appear to have
an impact on OS in patients with metastatic disease who
are treated with platinum-based chemotherapy. On the
basis of our ﬁndings, we believe that the importance of
FGFR3 as a driver of tumor growth and progression in
metastatic UC is unclear, and further functional evidence
is required to support this hypothesis.
The frequency of FGFR3 mutation in our cohorts is
low, with 2% in primary tumors and 9% in metastases,
although the sample size was small and the conﬁdence
intervals are wide. A recent study by Gust et al. reported
FGFR3 mutations in 11% (10/95) of cases of high-grade
invasive UC [14]. Ross et al. also recently published their
ﬁnding of FGFR3 mutations in 6% (2/35) cases of high-
grade metastatic muscle-invasive disease, both of which
were detected in primary tumors [15]. In contrast, previ-
ous reports have found FGFR3 mutations in up to 20%
of muscle-invasive UC using mass spectrometry-based
genotyping assay and 15% using sequencing [3, 16].
While Al-Ahmadie et al. used frozen tumors, the majority
of which were from cystectomy cases for their mutation
analysis, Tomlinson et al. performed their studies on
FFPE tissue, although they did not specify whether these
were TURBT or cystectomy samples. Thus, the use of
FFPE tissue in our study is unlikely to be the reason for
the lower mutation rate among our samples. Unlike Al-
Ahmadie et al., we did not perform Sanger sequencing of
all FGFR3 coding exons. However, the mutations identi-
ﬁed in their study and in the work by Tomlinson et al.
were included in our OncoMap and MIP platforms. The
majority of our samples came from patients in Greece
and Spain, raising the possibility that differences in expo-
sures between these populations and those studied by Al-
Ahmadie et al. and Tomlinson et al. may account for the
differences in the mutation proﬁle of these cohorts.
The most frequently identiﬁed FGFR3 mutation in our
study was Y373C, followed by R248C. Other studies have
reported S249C as the most commonly identiﬁed FGFR3
mutation, with lower frequencies of Y375C and R248C
(10–20%) [3, 17–19]. The majority of patients in these
studies had low-grade, nonmuscle-invasive disease in con-
trast to our muscle-invasive cohort. Thus, changes in
tumor biology reﬂected by differences in grade or stage
may account for some of this discrepancy. Although we
only identiﬁed four FGFR3 mutants among 161 primary
UC tumors and three mutants among 33 metastases,
tumors with FGFR3 mutations in our study showed a sta-
tistically signiﬁcant increase in FGFR3 mRNA levels and a
trend toward increased FGFR3 protein expression by
IHC, similar to what has been observed in nonmuscle-
invasive disease [3, 20]. This preliminary ﬁnding of an
association between FGFR3 mutation and protein expres-
sion requires conﬁrmation in a larger cohort of tumors
with FGFR3 mutations.
Figure 2. Immunohistochemical staining of FGFR3 in primary and
metastatic tumors. Negative staining = 0, weak = 1, weak–
moderate = 2, moderate = 3, strong = 4. *P = NS by Fisher’s exact
test (two tailed) between negative and any positive staining.
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tion analysis of FGFR3 was performed by hotspot
sequencing using two different technologies, OncoMap
and MIP array, rather than whole exon sequencing based
on when the work was performed and technology avail-
able at that time; older samples were tested using Oncom-
ap, and OncoScan was used when more recent samples
became available. Among the eight tumors tested for
mutations using both platforms, one tumor had a discor-
dant result with Y373C mutation detected using OncoM-
ap (iPLEX and hME) but the mutation, while detected in
OncoScan, did not reach the frequency threshold for pos-
itivity. This discordance may reﬂect low tumor purity,
heterogeneity, or subclonality within the tumor specimen.
Since representative tissue cores were obtained from
pathologist-reviewed tumor specimens and incorporated
into a TMA, our results do not rule out heterogeneous
staining and/or mutation proﬁles within tumors. In addi-
tion, no external validation of our results was possible, as
no other clinically annotated cohort of patients with pri-
mary or metastatic UC was available for analysis.
It is important to note is that no established cutoffs
have been developed for FGFR3 IHC staining. We
reported any staining as “positive” based on a previous
report [3], although many of our specimens showed weak
staining. In contrast, other studies required positive
FGFR3 staining in at least 5% of cells for a specimen to
be considered positive [17, 21]. Despite using the same
threshold for positivity, though, these groups reported
different percentages of positive staining tumors ranging
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Figure 3. OS and FGFR3 staining in primary and metastatic tumors. (A) FGFR3 staining was not associated with a difference in OS in the primary
tumor cohort (P = 0.89). (B) FGFR3 staining was not associated with differences in OS from time of disease recurrence in the metastatic tumor
cohort (P = 0.78).
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moderately or poorly differentiated) [17] to 49.2% of
high-grade pT2 UC [18].
Thus, despite a more inclusive threshold for positive
FGFR3 staining, our observation that 29% of the primary
tumors in our cohort had positive FGFR3 staining is rea-
sonable based on the published literature. Finally, the
majority of patients in our cohorts received platinum-
based combination chemotherapy and thus their tumors
may not be representative of the biology of UC in
patients unable to receive chemotherapy due to impaired
performance status.
Several lines of preclinical data suggest that FGFRs hold
promise as therapeutic targets in UC. FGFR3 and FGFR1
are either mutated or overexpressed in the majority of
nonmuscle-invasive UC [22], and in a percentage of mus-
cle-invasive UC [17, 23]. Furthermore, inhibition of FGF
signaling in both FGFR3 mutant and WT cell lines results
in reduced proliferation, thus suggesting a role for FGFR3
“oncogene addiction” that is independent of mutation
status [24, 25]. However, the clinical results to date have
been disappointing. A phase II study of TKI258 (doviti-
nib), an oral inhibitor of FGFR3, VEGFR, and PDGFR,
was recently terminated due to limited single agent activ-
ity in pretreated, advanced UC patients (NCT00790426),
including in the cohort with a presumed FGFR3 muta-
tion, despite encouraging in vitro inhibition of tumor
proliferation [26]. Other agents currently in development
that may demonstrate increased clinical activity include
pan-FGF inhibitors, dual FGFR, and VEGFR inhibitors
and FGFR-speciﬁc antibodies conjugated to the gelonin
toxin [27]. The discrepancy between promising in vitro
studies and lack of clinical beneﬁt may reﬂect either lack
of target speciﬁcity of the drug, that is, the wrong drug
for the right target, or a lack of understanding of how
FGFRs contribute to UC, which in turn prevents identiﬁ-
cation of a sensitive subset of tumors. Recent work dem-
onstrates that FGFR3 fusion with transforming acid
coiled coil 3 (TACC3) via 4p16.3 and t(4:7) rearrange-
ments result in receptor activation independent of FGFR3
mutation or overexpression and confer sensitivity to
FGFR-selective agents [28]. This work suggests that chro-
mosomal translocations, rather than mutational status or
expression alone, could be predictive of response to FGFR
inhibition. Furthermore, these fusions were identiﬁed in
less than 10% of lines studied (4 of 43 and 2 of 32,
respectively) [28]. FGFR3 fusions (FGFR3-TACC3 and
FGFR3-JAKMIP1) were recently identiﬁed in 5.7% (2/35)
cases of high-grade metastatic muscle-invasive disease
[15]. Thus, small unselected phase II studies are unlikely
to include patients whose tumors may be driven by these
translocations.
FGFR3 IHC staining does not appear to have prognos-
tic or predictive value in patients with metastatic UC.
This ﬁnding, however, does not eliminate FGFR3 as a
potential therapeutic target in metastatic disease. While
FGFR3 staining is rarely intense, the presence of detect-
able protein in primary and metastatic tumors suggests
that FGFR3 might be targeted by an antibody-mediated
approach and result in successful growth inhibition, as
Figure 4. FGFR3 copy number and mRNA expression for FGFR3
mutant and wild-type (WT) tumors. The Nanostring read counts for all
patients with loss, gain, or normal FGFR3 copy numbers are visualized
with dots for WT tumors and triangles for FGFR3 mutants. In
addition, the distributions of read counts in the three categories are
visualized with box plots.
Table 3. Frequency and type of FGFR3 mutations in primary tumors
and metastases.
FGFR3 mutations
observed: N
FGFR3 mutant%
(95% CI) P
Primary tumor
(N = 161)
R248C: 2 Y373C: 2 2% (1–6%) 0.1
Metastasis
(N = 33)
Y373C: 3 9% (2–24%)
Table 4. DNA copy number variation of FGFR3 by tissue type.
Tissue FGFR3 gain FGFR3 loss
Normal bladder tissue (N = 37) 0 0
Primary tumor (N = 121) 1 (0.8%) 1 (0.8%)
Metastasis (N = 33) 1 (3.0%) 4 (12.1%)
FGFR3 mutant (N = 6) 1 (16.7%) 0
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predictive biomarkers with which to identify tumors that
are dependent on FGFR3 signaling [14].
In summary, FGFR3 expression is present in both pri-
mary and metastatic UC, and the majority of metastases
retain IHC expression of FGFR3 if it was expressed in the
primary tumor. While FGFR3 mutation or copy number
gain is a rare event, studies of these tumors may shed
light on how FGFR3 signaling contributes to UC growth
and proliferation. Furthermore, based on preclinical stud-
ies that suggest the FGFR pathway, and speciﬁcally
FGFR3, may be a valid therapeutic target, we believe this
area of investigation warrants further exploration.
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